Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KIF5B | P33176 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681218 | 0.91 | EGFR (0.44) | EGFRKDRRETKIF5BMAP2K1 | |
| SCHEMBL346016 | 0.86 | MAP2K1 (0.49) | MAP2K1 | |
| SCHEMBL1681534 | 0.85 | MAP2K1 (0.42) | MAP2K1ALDH1A1TDP1L3MBTL1MEN1 | |
| SCHEMBL1681083 | 0.82 | MAP2K1 (0.39) | EGFRKDRMAP2K1ALDH1A1MEN1 | |
| SCHEMBL1979694 | 0.79 | KDR (0.48) | EGFRKDRRETKIF5BMAP2K1 | |
| SCHEMBL1681646 | 0.76 | MAP2K1 (0.49) | MAP2K1ALDH1A1MAPK1 | |
| SCHEMBL11908624 | 0.74 | KDR (0.48) | EGFRKDRRETKIF5BMAP2K1 | |
| SCHEMBL392951 | 0.73 | MAP2K1 (0.47) | MAP2K1MAPK1 | |
| SCHEMBL1578595 | 0.73 | MAP2K1 (0.43) | KDRMAP2K1MAPK1 | |
| SCHEMBL1578901 | 0.73 | MAP2K1 (0.43) | MAP2K1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2509964-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070030-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | BRAF, NRAS, MAP3K1 | EGFR 252/4885KDR 1342/4885RET 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.